Class A common stock
- Symbol
- APYX
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
Apyx Medical Corporation
APYXNASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events On September 29, 2026, Apyx Medical Corporation (the “Company”) issued a press release announcing the publication of new clinical data in Plastic and Reconstructive Surgery - Global Open highlighting results from a prospective clinical study evaluating the effects of Renuvion helium plasma radiofrequency technology on biological markers of skin quality.…
Press release in this filing
Apyx Medical Announces New Clinical Study Demonstrating Renuvion®’s Impact on Skin Quality →Recent company filings
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security HoldersAug 7, 2026
- 10-Q filingAug 6, 2026
- Results of Operations and Financial ConditionAug 6, 2026
- Other EventsJul 24, 2026
- SCHEDULE 13G/A - filed by ROYCE & ASSOCIATES LP regarding Apyx Medical CorpJul 21, 2026
Registered securities in this filing
APYX MEDICAL CORPORATION · 8-K · Filed 2026-09-29
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01
Other Events
On September 29, 2026, Apyx Medical Corporation (the “Company”) issued a press release announcing the publication of new clinical data in Plastic and Reconstructive Surgery - Global Open highlighting results from a prospective clinical study evaluating the effects of Renuvion helium plasma radiofrequency technology on biological markers of skin quality. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.